Zomedica SVP buys 150,000 shares at $0.097; now 5,784,101

Zomedica Corp. (ZOMDF) reported an insider purchase on a Form 4.

Rhea-AI Filing Summary

Zomedica Corp. (ZOMDF) reported an insider purchase on a Form 4. Senior Vice President, Sales, Kevin Klass bought 150,000 shares of common stock on November 13, 2025 at $0.097 per share. Following the transaction, he beneficially owned 5,784,101 shares, held directly.

Insider Trade Summary

Net Buyer: 150,000 shares

Net Buy 1 txn

Insider Klass Russell Kevin

Role Sr Vice President, Sales

Bought 150,000 shs ($15K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, without par value	150,000	$0.097	$15K

Holdings After Transaction: Common Stock, without par value — 5,784,101 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ZOMDF report?

A Senior Vice President purchased 150,000 Zomedica common shares.

What was the purchase price per share for ZOMDF?

The insider bought shares at $0.097 per share.

When did the ZOMDF insider purchase occur?

The transaction date was November 13, 2025.

How many ZOMDF shares does the insider own after the trade?

Post-transaction beneficial ownership is 5,784,101 shares.

Is the ZOMDF insider ownership direct or indirect?

The filing indicates direct ownership.

Who made the ZOMDF insider purchase and what is their role?

Kevin Klass, Senior Vice President, Sales, made the purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/14/2025 - 08:17 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klass Russell Kevin

(Last) (First) (Middle)

1101 TECHNOLOGY DRIVE, STE 100

(Street)

ANN ARBOR MI 48108

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zomedica Corp. [ ZOMDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr Vice President, Sales

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, without par value	11/13/2025		P		150,000	A	$0.097	5,784,101	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Kevin Klass	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.